Seattle Genetics Accelerates Revenue Growth, Earnings Not So Much

Seattle Genetics (NASDAQ:SGEN) posted solid revenue gains in the first quarter of the year, but it was guidance for the second quarter that had investors excited about how the biotech's lead drug, Adcetris, is finally reaching its potential.